All,
This press release announces our preliminary 2021 finish. We are releasing this data in conjunction with the JP Morgan Healthcare Conference that is being held this week. Releasing our preliminary results now allows us to discuss the business a little more broadly with investors and provide more context to the business. As noted in the PR these are not yet audited numbers which is why we provided a revenue range.
Bioventus finished Q4 between $128.5M and $131.5M and finished the full year between $429M and $432M. This represents growth of approximately 34% for the year and for those keeping track this is at or above the top of our guidance we gave in our November earnings call. More detailed information on our performance will come after our Q4 earnings release in early March.
The business finished a stellar 2021 with a stellar finish to the year! A true tribute to the resiliency of our company! This is a credit to the entire organization and we should all be proud of the results, the significant above market growth and the fact many more patients were positively impacted due to your focus on making sure our medical devices get into the hands of the patients that need them and returning them to Active Healthy Lives! Everyone makes this happen and please note the entire organization deserves ample credit for our achievement!
The commercial team deserves special commendation for this achievement as they always lead the charge on Revenue performance and our driving the forward progress of our momentum!
A special shout out to John Nosenzo our Chief Commercial Officer for his leadership and drive throughout the year!
Also a special thank you and congratulations to all of our sales and marketing leaders who worked throughout the year to drive our culture of Results and also Caring and Learning with our field sales teams.
And one more shout out to our Field Sales Team and ALL of those that met and beat your quota and delivered on your number! Well done!
I am closing this message to briefly highlight our 2022 AOP (Annual Operating Plan) and more will come on this.
Our total revenue goal is $581M for 2022 with an EBITDA number of $106M (please note this includes a full year of Bioness and Misonix).
Can we do it? Of course we can!!! Can we hit $600M? Maybe we can….it will be about gaining double digit growth across the entire business!
We will do it one step at a time and focus on gaining Results, Caring about each other (and our patients) and Learning as we continue to get better as we go forward.
Wishing you a terrific start to 2022, a Growth Mindset and look forward to a fantastic year!
Best Regards,
Ken